Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

Rhea-AI Summary

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, July 23, 2024, at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution. The event will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Interested individuals can register for telephone participation, and upon registration, will receive confirmation details including a unique passcode and registrant ID. A replay of the event will be available on Kiniksa's website within approximately 48 hours after the event.

LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST^®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ^®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com

FAQ

When will Kiniksa Pharmaceuticals (KNSA) report its Q2 2024 financial results?

Kiniksa Pharmaceuticals (KNSA) will report its second quarter 2024 financial results on Tuesday, July 23, 2024, at 8:30 a.m. Eastern Time.

How can investors access Kiniksa Pharmaceuticals' (KNSA) Q2 2024 earnings call?

Investors can access Kiniksa Pharmaceuticals' Q2 2024 earnings call through a live webcast on the company's website at www.kiniksa.com in the Investors & Media section, or by registering for telephone participation.

Will there be a replay available for Kiniksa Pharmaceuticals' (KNSA) Q2 2024 earnings call?

Yes, a replay of Kiniksa Pharmaceuticals' (KNSA) Q2 2024 earnings call will be available on the company's website within approximately 48 hours after the event.